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ABSTRACT
Visceral leishmaniasis is rare in western Europe, but may be life-threatening in immunocompromised
patients. It is therefore important to understand the incidence of the disease in a non-endemic area and
its relationship with immunosuppressive conditions. Between 1990 and 2005, 12 patients were
diagnosed with leishmaniasis at Basel University Hospital, Switzerland. Eleven presented with visceral
symptoms and ten had an underlying immunosuppressive condition. Since increasing numbers of
immunosuppressed patients have a history of travel to endemic countries, an association of visceral
leishmaniasis with cellular immunosuppression (other than that associated with human immunode-
ficiency virus) might become more frequent in non-endemic areas.
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The clinical presentation and course of visceral
leishmaniasis depend on complex interactions
between the parasite and host [1]. Classic
symptoms are night sweats, weight loss, hepato-
splenomegaly and pancytopenia. Control of
infection is achieved via leishmania-specific CD4
T-cells of the TH1 type and the activation of
macrophages to kill the intracellular amastigotes
[2]. A strong cellular immune response leads to
the formation of granulomas with few parasites
and an asymptomatic or oligo-symptomatic
disease. In cases of malnutrition or immuno-
suppression, macrophage predominance, lack of
granulomas and poly-parasitic disease are seen,
with severe symptoms and occasional deleterious
clinical outcomes.
Reactivation of leishmaniasis following cellular
immunosuppression is a particular diagnostic and
therapeutic challenge [3–9]. With an increasing
incidence of travel and migration, leishmaniasis
might become more frequent in patients with
immunosuppressive conditions in non-endemic
regions. In order to better understand the inci-
dence of the disease in a non-endemic area, and its
relationship with immunosuppressive conditions,
the databases of the Division of Infectious
Diseases and the Department of Pathology at
University Hospital of Basel, Switzerland were
searched for documented cases of infection with
Leishmania spp. Medical charts and histopatho-
logical examinations were also analysed. Twelve
patients (eight male and four female), aged
22–71 years (median age 42 years), were diag-
nosed with leishmaniasis during the period 1990–
2005, with 11 patients having a visceral form and
one patient having a mucocutaneous form of
the disease. Leishmaniasis was confirmed by
histology in 11 patients (bone marrow, liver),
while serology was the only test performed for one
patient. PCR results were available for six cases,
with four Leishmania infantum isolates, one
Leishmania donovani isolate and one Leishmania
braziliensis isolate being identified.
Ten of the 12 patients had an immunosuppres-
sive condition as an underlying disease. Four
patients suffered from advanced infection (CD4
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cell count <100 ⁄mm3) with human immuno-
deficiency virus; none of these patients was
receiving anti-retroviral therapy, and three pre-
sented before the introduction of anti-retroviral
therapy. Six other patients were receiving immu-
nosuppressive therapy. Of these six patients, two
had haematological malignancies; one received
fludarabin for non-Hodgkin’s lymphoma, and
one was aplastic following high-dose chemother-
apy for newly diagnosed acute lymphatic leuk-
aemia. This second patient developed severe
intestinal mucositis that necessitated surgical
intervention, with a biopsy revealing invasive
infection with L. braziliensis. A third patient, with
leishmaniasis involving the tongue, underwent a
thymectomy with local radiation treatment for
malignant thymoma 9 years before the onset of
infection. The initial diagnosis of a fourth patient
was allopurinol-associated granulomatous hepa-
titis [10], which was treated with steroids. One
month later, a second liver biopsy, performed
because of pancytopenia and fever, revealed
L. infantum, but with disappearance of granulo-
mas. Reactivation of a latent Leishmania infection
was postulated. Diabetes mellitus was the only
immunosuppressive condition found in the fifth
patient. Finally, the sixth patient had severe acute
mononucleosis, diagnosed by positive antibodies
(IgM and IgG) to early Epstein–Barr virus anti-
gens. Infection with Leishmania was diagnosed
serologically during investigation of persisting
fever, weight loss, hepatopathy and pancytope-
nia, and this patient improved following anti-
leishmanial treatment. It is of interest that an
association of Epstein–Barr virus infection with
Leishmania has not been described previously in
the literature, but herpes viruses are known to
exacerbate immune impairment in solid-organ
transplants, increasing the risk of activation of co-
infecting agents [11]. It can be hypothesised that
Epstein–Barr virus infection, with its complex
immune activation, interacts at the cytokine level
with defence strategies against Leishmania.
No clear underlying disease was found in two
patients: one patient with histologically diagnosed
(bone marrow, liver and spleen) leishmaniasis,
who showed recovery following anti-leishmanial
treatment, presented several times during the
following years with unexplained fever without
recurrence or an underlying disease; the other
patient had no obvious impairment of immune
function, but was aged 80 years and had multiple
co-morbidities, e.g., coronary heart disease, local-
ised prostate cancer and severe pneumonia.
All patients had a history of migration from or
travel to an endemic area. Seven patients were
originally from Mediterranean countries, where
dogs are a major reservoir of Leishmania [12]. The
five patients from Switzerland and Germany also
had a history of travel.
Data concerning outcome were available for all
patients. Three patients were treated with intra-
venous pentamidine, four received meglumine
antimoniate, and six were treated with liposomal
amphotericin B. Four patients died shortly after
the diagnosis and start of treatment for leishmani-
asis, demonstrating the severity of infection in the
presence of immunosuppression and the high
failure rate of antimicrobial therapy in such
situations [13]: one died of advanced infection
and untreated human immunodeficiency virus
infection; a second developed a fatal bleeding
complication after splenectomy, with progressive
renal failure and nosocomial pneumonia; a third
was treated for acute lymphatic leukaemia and
developedmulti-organ failure; and the fourth died
from acute liver failure. In this retrospective
analysis, it was impossible to assess the specific
outcome regarding leishmaniasis, as all these
patients had severe underlying conditions. The
eight remaining patients were discharged, but
three patients with AIDS died later because of
advanced immunosuppression. The patient with
leishmaniasis of the tongue presented with a
recurrence of the infection after 3 years [14]. Four
patients remained well at follow-up.
Before the era of anti-retroviral therapy, AIDS
was a common risk-factor for symptomatic
visceral leishmaniasis. However, the present ana-
lysis identified a significant proportion of patients
with less well-known risk-factors, e.g., malignant
disorders, high-dose chemotherapy, treatment
with radiation and steroids. As such therapies
become more frequent, and as current therapies
have fewer side-effects, thereby allowing patients
to travel to countries in which Leishmania is
endemic, an increase in infections with Leishmania
in non-endemic countries may be expected. A
delay of up to 10 years between exposure and the
start of symptoms was found. An immunosup-
pressive condition was found in ten of the 12
patients analysed, confirming that symptoms of
visceral leishmaniasis develop mostly in the
presence of cellular immunodeficiency, whereas
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a normal immune system is often capable of
controlling the infection. As the present analysis
selected cases according to the histological diag-
nosis, the patients comprised a series with severe
illness, having been hospitalised for diagnosis
and treatment, whereas less ill patients, diag-
nosed by less invasive methods (e.g., serology,
PCR) in an outpatient setting, might have been
overlooked. Nevertheless, this analysis yielded
clear information: in patients with a history of
migration or travel to endemic areas in conjunc-
tion with an underlying immunosuppressive
condition, the exclusion of Leishmania infection
should be mandatory in the event of unexplained
fever, hepato-splenomegaly and ⁄ or cytopenia.
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